Finance Watch: Public Companies Pursue All Options To Fund R&D, Launches

The usual pattern of reporting positive clinical trial results or winning US Food and Drug Administration approval then launching a large follow-on public offering (FOPO) has become less common under current financial market conditions, but biopharmaceutical companies are finding plenty of alternative ways to fund their next crucial clinical trials or product launches.

For instance, Amicus Therapeutics, Inc. won FDA approval on 28 September for Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) for late-onset Pompe disease, then said on 2 October that it entered into a “strategic financing collaboration” with funds managed by Blackstone for $430m to support the Pombiliti + Opfolda launch and the company’s other rare disease products and development programs